Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, and other mental health disorders. The company's product candidates include COMP360, BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, a transmucosal film in Phase 2 clinical study; and ELE-101, a serotonergic psychedelic for the treatment of treatment resistant depression. It also EMP-01, an oral formulation of an R-MDMA that Is in phase 2 clinical study; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, the company offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, for the treatment of generalize anxiety disorder. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Market Cap	$1.59B	P/E Ratio	N/A
52W High	$6.75	52W Low	$1.15
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	8.4%	52W Position	56.1%
Overall Score	42	Value Score	40
Quality Score	34	Technical Score	54

EPS Current Est	$-0.67	EPS Next Est	$-0.55
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATAI	$4.29	-2.94%	3.01M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATAI	$4.29	-2.9%	3.01M
3
4
5
6

ATAI

ATAI

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ATAI Life Sciences N.V. Data in Excel

Get ATAI Life Sciences N.V. Data in Excel